Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(3.2%)
USD 4.19
(3.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.27 Million USD | -11.14% |
| 2022 | -5.65 Million USD | -0.95% |
| 2021 | -5.59 Million USD | 15.53% |
| 2020 | -6.62 Million USD | 28.07% |
| 2019 | -9.21 Million USD | -32.29% |
| 2018 | -6.96 Million USD | 12.73% |
| 2017 | -7.97 Million USD | -744.58% |
| 2016 | -944.68 Thousand USD | -229.17% |
| 2015 | 731.35 Thousand USD | -69.83% |
| 2014 | 2.42 Million USD | 215.16% |
| 2013 | -2.1 Million USD | -136.02% |
| 2012 | 5.84 Million USD | 3.26% |
| 2011 | 5.65 Million USD | 130.3% |
| 2010 | 2.45 Million USD | -20.53% |
| 2009 | 3.09 Million USD | -35.14% |
| 2008 | 4.76 Million USD | 17.85% |
| 2007 | 4.04 Million USD | -8.18% |
| 2006 | 4.4 Million USD | 125.37% |
| 2005 | 1.95 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.94 Million USD | 69.06% |
| 2024 Q2 | -1.08 Million USD | 44.22% |
| 2023 Q2 | 872.2 Thousand USD | 353.84% |
| 2023 Q4 | -6.29 Million USD | -499.55% |
| 2023 FY | -6.27 Million USD | -11.14% |
| 2023 Q3 | -1.04 Million USD | -220.3% |
| 2023 Q1 | 192.18 Thousand USD | 107.81% |
| 2022 Q2 | -1.36 Million USD | 2.69% |
| 2022 Q3 | -423.22 Thousand USD | 68.99% |
| 2022 FY | -5.65 Million USD | -0.95% |
| 2022 Q4 | -2.45 Million USD | -481.18% |
| 2022 Q1 | -1.4 Million USD | 63.55% |
| 2021 Q4 | -3.84 Million USD | -264.61% |
| 2021 Q3 | -1.05 Million USD | -185.9% |
| 2021 Q2 | 1.22 Million USD | 636.42% |
| 2021 Q1 | 166.82 Thousand USD | 118.88% |
| 2021 FY | -5.59 Million USD | 15.53% |
| 2020 Q3 | -481.73 Thousand USD | 47.54% |
| 2020 FY | -6.62 Million USD | 28.07% |
| 2020 Q1 | -1.05 Million USD | -9.88% |
| 2020 Q2 | -918.27 Thousand USD | 13.01% |
| 2020 Q4 | -883.77 Thousand USD | -83.46% |
| 2019 FY | -9.21 Million USD | -32.29% |
| 2019 Q1 | -73.87 Thousand USD | 96.67% |
| 2019 Q4 | -960.7 Thousand USD | 50.83% |
| 2019 Q3 | -1.95 Million USD | -255.53% |
| 2019 Q2 | -549.5 Thousand USD | -643.8% |
| 2018 Q1 | -2.37 Million USD | -197.2% |
| 2018 FY | -6.96 Million USD | 12.73% |
| 2018 Q4 | -2.22 Million USD | -35.12% |
| 2018 Q3 | -1.64 Million USD | -127.98% |
| 2018 Q2 | -720.68 Thousand USD | 69.71% |
| 2017 Q1 | -1.27 Million USD | -70.0% |
| 2017 FY | -7.97 Million USD | -744.58% |
| 2017 Q4 | -800.54 Thousand USD | -7.74% |
| 2017 Q3 | -743.03 Thousand USD | 85.6% |
| 2017 Q2 | -5.16 Million USD | -304.93% |
| 2016 Q2 | -48.04 Thousand USD | 81.02% |
| 2016 Q3 | 106.16 Thousand USD | 320.98% |
| 2016 Q4 | -749.69 Thousand USD | -806.15% |
| 2016 FY | -944.68 Thousand USD | -229.17% |
| 2016 Q1 | -253.11 Thousand USD | -267.56% |
| 2015 Q2 | 405.99 Thousand USD | 777.25% |
| 2015 FY | 731.35 Thousand USD | -69.83% |
| 2015 Q1 | 46.28 Thousand USD | -93.08% |
| 2015 Q4 | 151.05 Thousand USD | 19.31% |
| 2015 Q3 | 126.61 Thousand USD | -68.81% |
| 2014 Q4 | 668.91 Thousand USD | -10.32% |
| 2014 FY | 2.42 Million USD | 215.16% |
| 2014 Q2 | 722.57 Thousand USD | 152.36% |
| 2014 Q1 | 286.32 Thousand USD | 119.08% |
| 2014 Q3 | 745.92 Thousand USD | 3.23% |
| 2013 FY | -2.1 Million USD | -136.02% |
| 2013 Q4 | -1.5 Million USD | -82.98% |
| 2013 Q1 | 854.7 Thousand USD | -52.66% |
| 2013 Q2 | -639.01 Thousand USD | -174.76% |
| 2013 Q3 | -819.94 Thousand USD | -28.31% |
| 2012 Q1 | 423.2 Thousand USD | -53.58% |
| 2012 FY | 5.84 Million USD | 3.26% |
| 2012 Q2 | 1.74 Million USD | 312.16% |
| 2012 Q3 | 1.86 Million USD | 7.18% |
| 2012 Q4 | 1.8 Million USD | -3.42% |
| 2011 Q2 | 2.17 Million USD | 201.96% |
| 2011 Q4 | 911.66 Thousand USD | -50.65% |
| 2011 FY | 5.65 Million USD | 130.3% |
| 2011 Q3 | 1.84 Million USD | -15.16% |
| 2011 Q1 | 721.16 Thousand USD | -13.9% |
| 2010 Q3 | 1 Million USD | 250.93% |
| 2010 FY | 2.45 Million USD | -20.53% |
| 2010 Q4 | 837.55 Thousand USD | -16.93% |
| 2010 Q1 | 323.57 Thousand USD | 11.84% |
| 2010 Q2 | 287.3 Thousand USD | -11.21% |
| 2009 Q2 | 295.87 Thousand USD | -75.71% |
| 2009 Q1 | 1.21 Million USD | 10.38% |
| 2009 Q3 | 1.28 Million USD | 335.37% |
| 2009 FY | 3.09 Million USD | -35.14% |
| 2009 Q4 | 289.31 Thousand USD | -77.54% |
| 2008 Q2 | 1.05 Million USD | -24.14% |
| 2008 Q1 | 1.39 Million USD | 71.21% |
| 2008 Q4 | 1.1 Million USD | -8.72% |
| 2008 Q3 | 1.2 Million USD | 14.23% |
| 2008 FY | 4.76 Million USD | 17.85% |
| 2007 Q2 | 1.24 Million USD | 69.05% |
| 2007 Q1 | 739.1 Thousand USD | -78.81% |
| 2007 Q4 | 814.94 Thousand USD | -34.32% |
| 2007 Q3 | 1.24 Million USD | -0.69% |
| 2007 FY | 4.04 Million USD | -8.18% |
| 2006 FY | 4.4 Million USD | 125.37% |
| 2006 Q1 | -1.21 Million USD | 0.0% |
| 2006 Q4 | 3.48 Million USD | 129.11% |
| 2006 Q2 | 609.67 Thousand USD | 150.11% |
| 2006 Q3 | 1.52 Million USD | 149.76% |
| 2005 FY | 1.95 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 113.04% |
| Embecta Corp. | 70.4 Million USD | 108.919% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 133.438% |
| Dynavax Technologies Corporation | -6.38 Million USD | 1.717% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.999% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 114.967% |
| PainReform Ltd. | -9.34 Million USD | 32.798% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 20.212% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -39.353% |
| SCYNEXIS, Inc. | 67.04 Million USD | 109.366% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -102.655% |
| Cosmos Health Inc. | -18.54 Million USD | 66.136% |
| Journey Medical Corporation | -3.85 Million USD | -62.972% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -39.353% |
| Safety Shot Inc | -15.08 Million USD | 58.368% |
| Alpha Teknova, Inc. | -36.78 Million USD | 82.927% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 95.504% |
| Bright Green Corporation | -13.12 Million USD | 52.167% |
| Procaps Group, S.A. | 42.54 Million USD | 114.761% |
| Theratechnologies Inc. | -23.95 Million USD | 73.789% |
| Harrow Health, Inc. | -24.41 Million USD | 74.277% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -29.872% |
| Biofrontera Inc. | -20.13 Million USD | 68.808% |
| DURECT Corporation | -27.62 Million USD | 77.269% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 577.152% |
| Cronos Group Inc. | -73.96 Million USD | 91.51% |
| OptiNose, Inc. | -35.48 Million USD | 82.303% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.373% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 85.12% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 126.256% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 226.983% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 4073.423% |
| Radius Health, Inc. | -25.79 Million USD | 75.653% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -1.886% |
| ProPhase Labs, Inc. | -16.78 Million USD | 62.583% |
| Phibro Animal Health Corporation | 2.41 Million USD | 359.906% |
| Procaps Group S.A. | 42.54 Million USD | 114.761% |
| Alvotech | -551.73 Million USD | 98.862% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 38.905% |
| Viatris Inc. | 54.7 Million USD | 111.48% |
| Rockwell Medical, Inc. | -8.43 Million USD | 25.592% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 60.368% |
| SIGA Technologies, Inc. | 68.06 Million USD | 109.225% |
| Tilray Brands, Inc. | -244.98 Million USD | 97.437% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 152.271% |
| Shineco, Inc. | -22.44 Million USD | 72.029% |
| PetIQ, Inc. | 2.13 Million USD | 394.665% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -45.968% |
| Incannex Healthcare Limited | -18.45 Million USD | 65.982% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 102.515% |
| Alimera Sciences, Inc. | -20.13 Million USD | 68.809% |
| Silver Spike Investment Corp. | 7.34 Million USD | 185.548% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.108% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 4.754% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 23.078% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 64.918% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 68.693% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 96.082% |
| Hempacco Co., Inc. | -13.12 Million USD | 52.162% |
| Talphera, Inc. | -18.39 Million USD | 65.868% |
| Alvotech | -551.73 Million USD | 98.862% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 117.618% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.922% |
| Currenc Group, Inc. | -15.3 Million USD | 58.976% |
| Kamada Ltd. | 8.28 Million USD | 175.801% |
| Indivior PLC | 2 Million USD | 413.966% |
| Evoke Pharma, Inc. | -7.79 Million USD | 19.416% |
| Flora Growth Corp. | -57.03 Million USD | 88.991% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 68.693% |
| Evolus, Inc. | -61.68 Million USD | 89.82% |
| HUTCHMED (China) Limited | 100.78 Million USD | 106.231% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 104.565% |
| Akanda Corp. | -32.27 Million USD | 80.544% |